2.1 Diabetes Mellitus: Diagnosis, Glycemic Targets & Pharmacotherapy
Key Takeaways
- The diabetes mellitus blueprint subsection enumerates type 1, type 2, diabetes in pregnancy, and complications of diabetes.
- Diagnosis requires a hemoglobin A1c of 6.5% or higher, fasting glucose of 126 mg/dL or higher, a two-hour value of 200 mg/dL or higher, or a random glucose of 200 mg/dL or higher with classic symptoms.
- Metformin remains first line for glycemic control, but agent selection is dominated by comorbidity rather than by A1c-lowering potency.
- SGLT2 inhibitors are indicated for albuminuric chronic kidney disease and heart failure independent of the A1c value.
- Hemoglobin A1c is unreliable in hemoglobinopathies, recent transfusion, hemolysis, iron deficiency and advanced kidney disease, where fructosamine or glucose monitoring is used instead.
Diabetes mellitus represents a group of metabolic disorders characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. For the ABIM certification examination, mastery of diagnostic thresholds, individualized glycemic targets, organ-protective pharmacotherapy selection, emergent DKA/HHS management protocols, and chronic complication surveillance is essential.
1. Diagnostic Criteria & Screening Guidelines
Formal Diagnostic Criteria
According to the American Diabetes Association (ADA) Standards of Care, diagnosis requires one of the following criteria. In the absence of unequivocal symptomatic hyperglycemia (polyuria, polydipsia, polyphagia, unintentional weight loss), a diagnosis requires two abnormal test results from the same sample or two separate test samples:
| Test | Normal | Prediabetes | Diabetes Mellitus |
|---|---|---|---|
| Fasting Plasma Glucose (FPG) | < 100 mg/dL (5.6 mmol/L) | 100–125 mg/dL (5.6–6.9 mmol/L) (IFG) | >= 126 mg/dL (7.0 mmol/L) (fasting >=8 hr) |
| 2-Hour 75g OGTT | < 140 mg/dL (7.8 mmol/L) | 140–199 mg/dL (7.8–11.0 mmol/L) (IGT) | >= 200 mg/dL (11.1 mmol/L) |
| Hemoglobin A1c (HbA1c) | < 5.7% (39 mmol/mol) | 5.7%–6.4% (39–47 mmol/mol) | >= 6.5% (48 mmol/mol) (NGSP-certified) |
| Random Plasma Glucose | — | — | >= 200 mg/dL (11.1 mmol/L) + classic symptoms |
Board Exam Pearl (HbA1c Discrepancies): Conditions that alter erythrocyte turnover invalidate HbA1c. Hemoglobinopathies (sickle cell trait/disease), hemolytic anemia, recent blood transfusion, severe blood loss, and hemodialysis falsely lower HbA1c. Severe iron deficiency anemia and asplenia falsely elevate HbA1c. In these clinical scenarios, rely on fasting/prandial plasma glucose measurements, continuous glucose monitoring (CGM), or serum fructosamine / glycated albumin (reflects 2–3 week glycemic control).
Screening Recommendations
- General Population: Screen all asymptomatic adults starting at age 35 (USPSTF/ADA), repeating every 3 years if normal.
- Overweight/Obese Adults (BMI >=25 kg/m2, or >=23 kg/m2 in Asian Americans): Screen at any age if >=1 additional risk factor is present: first-degree relative with diabetes, high-risk ethnicity (Black, Hispanic, American Indian, Asian American), history of cardiovascular disease, hypertension (>=130/80 mmHg or on therapy), HDL-C <35 mg/dL and/or triglycerides >250 mg/dL, polycystic ovary syndrome (PCOS), physical inactivity, or history of gestational diabetes mellitus (GDM; rescreen lifelong every 3 years).
- Prediabetes Management: Intensive lifestyle intervention (7% weight loss, >=150 min/week moderate-intensity physical activity) reduces diabetes incidence by 58%. Metformin is specifically indicated for prediabetes in those aged 25–59 years with BMI >=35 kg/m2, higher fasting glucose (>=110 mg/dL), higher HbA1c (>=6.0%), or women with prior GDM.
2. ADA Glycemic Targets & CGM Metrics
Glycemic targets must be strictly individualized based on duration of diabetes, age/life expectancy, comorbid conditions, established vascular complications, hypoglycemia risk/awareness, and patient resources.
Standard vs. Individualized Glycemic Goals
| Clinical Context | HbA1c Target | Preprandial Capillary Glucose | Peak Postprandial Capillary Glucose (1–2 hr) |
|---|---|---|---|
| General Nonpregnant Adult | < 7.0% (53 mmol/mol) | 80–130 mg/dL (4.4–7.2 mmol/L) | < 180 mg/dL (10.0 mmol/L) |
| Stringent Goal (Young, newly diagnosed, long life expectancy, no ASCVD, no hypoglycemia risk) | < 6.5% (48 mmol/mol) | 70–110 mg/dL | < 140 mg/dL |
| Less Stringent Goal (History of severe hypoglycemia, hypoglycemia unawareness, limited life expectancy, advanced micro/macrovascular complications, extensive comorbidities) | < 8.0% (64 mmol/mol) | 100–150 mg/dL | < 200 mg/dL |
| Frail Elderly / End-of-Life | Avoid hypoglycemia & symptomatic hyperglycemia (A1c target not primary focus; up to <8.5%) | 100–180 mg/dL | < 250 mg/dL |
Continuous Glucose Monitoring (CGM) Ambulatory Glucose Profile (AGP) Targets
For most non-pregnant adults using CGM, standard international consensus targets include:
- Time in Range (TIR: 70–180 mg/dL [3.9–10.0 mmol/L]): > 70% (every 10% increase in TIR correlates with ~0.8% reduction in HbA1c and reduced microvascular risk).
- Time Below Range (TBR Level 1: 54–69 mg/dL): < 4% (~1 hour/day).
- Time Below Range (TBR Level 2: < 54 mg/dL): < 1% (~15 minutes/day).
- Time Above Range (TAR Level 1: 181–250 mg/dL): < 25%.
- Time Above Range (TAR Level 2: > 250 mg/dL): < 5%.
- Glycemic Variability (%CV): Target <= 36%.
3. Antihyperglycemic Pharmacotherapy
Class-by-Class Comparative Analysis
+---------------------------------------------------------------------------------------------------------+
| CLASS / AGENTS | PRIMARY MECHANISM | CLINICAL BENEFITS | RISKS / ADVERSE EFFECTS |
+----------------------+----------------------------+--------------------------+---------------------------+
| Biguanides | Inhibits hepatic | Weight neutral; no | GI distress (diarrhea); |
| - Metformin | gluconeogenesis via AMPK; | hypoglycemia monotherapy;| Vitamin B12 deficiency; |
| | improves peripheral insulin| modest CV mortality | Lactic acidosis risk |
| | sensitivity | benefit | (avoid if eGFR < 30) |
+----------------------+----------------------------+--------------------------+---------------------------+
| SGLT2 Inhibitors | Inhibits SGLT2 in renal | Major reduction in HF | Mycotic genital infections|
| - Empagliflozin | proximal tubule -> enhances| hospitalizations, CKD | Volume depletion / AKI; |
| - Dapagliflozin | urinary glucose excretion | progression, and CV death| Euglycemic DKA (euDKA); |
| - Canagliflozin | & osmotic diuresis | (independent of baseline | Fournier gangrene |
| | | HbA1c); weight loss | |
+----------------------+----------------------------+--------------------------+---------------------------+
| GLP-1 Receptor | Activates GLP-1 receptor ->| Significant ASCVD event | Nausea, vomiting, diarrhea|
| Agonists | glucose-dependent insulin, | reduction (MACE), | Pancreatitis risk; |
| - Semaglutide (SQ/PO)| suppresses glucagon, | substantial weight loss | Medullary thyroid cancer |
| - Dulaglutide | slows gastric emptying, | (Semaglutide 15%), slows | & MEN 2 contraindication; |
| - Liraglutide | enhances satiety | CKD progression | Worsening retinopathy |
+----------------------+----------------------------+--------------------------+---------------------------+
| Dual GIP/GLP-1 RA | Co-agonism of GIP and | Exceptional HbA1c | GI disturbances (nausea, |
| - Tirzepatide | GLP-1 receptors -> | lowering (>2.0-2.5%) and | constipation, diarrhea); |
| | synergistic insulinotropism| profound weight loss | MTC / MEN 2 contra- |
| | and energy regulation | (>20% in SURMOUNT/SURPASS| indication |
+----------------------+----------------------------+--------------------------+---------------------------+
| DPP-4 Inhibitors | Inhibits DPP-4 enzyme, | Weight neutral; low | Nasopharyngitis; joint |
| - Sitagliptin | prolonging endogenous GLP-1| hypoglycemia risk; | pain; Saxagliptin |
| - Linagliptin | and GIP activity | well-tolerated | increases HF risk; |
| - Saxagliptin | | (Linagliptin: no renal | Do not combine with |
| | | adjustment needed) | GLP-1 RAs |
+----------------------+----------------------------+--------------------------+---------------------------+
| Thiazolidinediones | PPAR-gamma agonist -> | Durable glycemic control;| Fluid retention / edema; |
| - Pioglitazone | increases insulin | reduces recurrent stroke | Heart Failure exacer- |
| | sensitivity in muscle, fat,| risk (IRIS trial); | bation (Contraindicated in|
| | and liver | improves MASH/NASH | NYHA Class III/IV HF); |
| | | histology | Bone fractures; weight gain
+----------------------+----------------------------+--------------------------+---------------------------+
| Sulfonylureas | Closes ATP-sensitive K+ | Rapid glucose lowering; | Hypoglycemia; weight gain;|
| - Glimepiride | channels on beta cells -> | low cost | Avoid Glyburide in renal |
| - Glipizide | stimulates insulin release | | impairment (active |
| - Glyburide | | | metabolite accumulation) |
+----------------------+----------------------------+--------------------------+---------------------------+
Renal Dosing Thresholds & Critical Safety Rules
- Metformin: Obtain baseline eGFR prior to initiation. eGFR >=45 mL/min: Full dose (up to 2000–2550 mg/day). eGFR 30–44 mL/min: Max dose 1000 mg/day; do not start de novo. eGFR <30 mL/min: Contraindicated. Hold prior to iodinated contrast procedures in patients with eGFR <60 or hepatic dysfunction; restart after 48 hours if renal function remains stable.
- SGLT2 Inhibitors: Glycemic efficacy declines at eGFR <45 mL/min, but organ-protective cardiorenal benefits persist down to eGFR 20 mL/min. Hold SGLT2 inhibitors >=3–4 days prior to major elective surgery or extreme endurance athletics to prevent euglycemic DKA (caused by glycosuria masking severe insulinopenia while glucagon/ketogenesis surge).
- Sulfonylureas: Glipizide is metabolized by the liver to inactive metabolites and is the preferred sulfonylurea in CKD. Glyburide produces active renally cleared metabolites and is contraindicated in renal insufficiency due to severe prolonged hypoglycemia.
A 62-year-old male with a 10-year history of type 2 diabetes mellitus presents for routine follow-up. His current medications are metformin 1000 mg twice daily and glimepiride 4 mg daily. His medical history is notable for ischemic cardiomyopathy with a left ventricular ejection fraction of 32% (NYHA Class II heart failure) and Stage 3a chronic kidney disease. Vital signs: blood pressure 128/76 mmHg, pulse 68 bpm. Physical examination reveals mild bilateral lower extremity trace edema and clear lungs. Laboratory testing reveals: serum creatinine 1.6 mg/dL, estimated GFR 42 mL/min/1.73m2, HbA1c 8.4%, and spot urine albumin-to-creatinine ratio (UACR) 185 mg/g. Which of the following is the most appropriate next step in pharmacotherapy?